Form 4: Citius Pharmaceuticals Director Suren G. Dutia Acquires 125,000 Stock Options
SEC Form 4 Filing
Director Suren G. Dutia of Citius Pharmaceuticals acquired 125,000 stock options on November 7, 2024, as reported in a recent SEC Form 4 filing.
Summary
- Suren G. Dutia, a director at Citius Pharmaceuticals, was granted 125,000 stock options on November 7, 2024.
- These options have an exercise price of $0.38 and will vest fully on the one-year anniversary of the grant date, provided Mr. Dutia remains in continuous service to the company.
- The filing also details other previously granted stock options held by Mr. Dutia, with varying exercise prices and expiration dates.
Sentiment
Score: 7
Explanation: The document reflects a routine stock option grant, which is generally viewed positively as it aligns director interests with shareholders. There are no negative implications.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the director.
Industry Context
Stock option grants are a common practice for incentivizing directors and aligning their interests with shareholders in the pharmaceutical industry.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for directors in publicly traded companies, including those in the pharmaceutical sector.
- The vesting schedule of one year is also a common practice to ensure long-term commitment.
- The exercise prices of the options are typical for companies in the biotechnology and pharmaceutical space, often reflecting the current market price and future growth potential.
Stakeholder Impact
- The stock option grant could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
- The vesting schedule encourages the director's continued service to the company.
Key Dates
| Date | Description |
|---|---|
| 11/07/2024 | Date of the stock option grant to Suren G. Dutia. |
| 11/07/2025 | Vesting date for the 125,000 stock options granted on November 7, 2024. |
| 10/01/2025 | Expiration date for some of the previously granted stock options. |
| 09/13/2027 | Expiration date for some of the previously granted stock options. |
| 09/04/2028 | Expiration date for some of the previously granted stock options. |
| 10/08/2029 | Expiration date for some of the previously granted stock options. |
| 07/07/2030 | Expiration date for some of the previously granted stock options. |
| 10/06/2030 | Expiration date for some of the previously granted stock options. |
| 02/16/2031 | Expiration date for some of the previously granted stock options. |
| 07/22/2031 | Expiration date for some of the previously granted stock options. |
| 10/11/2031 | Expiration date for some of the previously granted stock options. |
| 10/04/2032 | Expiration date for some of the previously granted stock options. |
| 10/10/2033 | Expiration date for some of the previously granted stock options. |
| 11/07/2034 | Expiration date for the 125,000 stock options granted on November 7, 2024. |
| 11/12/2024 | Date of the signature on the SEC Form 4 filing. |
Keywords
stock options, SEC Form 4, Citius Pharmaceuticals, director, insider trading, equity, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.